Blackman Samuel C.'s Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Nov 12, 2024
- Accession no.
- 0001415889-24-026624
- Filed
- Nov 12, 2024
- Trade date
- Nov 8-11, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $456.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Blackman Samuel C.CIK 0001863676 | Officer (HEAD OF R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2024 | Common Stock | SSaleDisposed | −18,255 | $16.17 | −$295,183.35 | 1,067,535 | Direct | |
| Nov 11, 2024 | Common Stock | SSaleDisposed | −10,000 | $16.10 | −$161,000 | 1,057,535 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.